Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aquestive (United States)
company in Warren Township, United States
Nothing else this week.
- FDA
-
SEC
Slovak company
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
Coverage
Newest first; wire copies grouped- GlobeNewswireAquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”